Rhythm Pharmaceuticals, Inc
Rhythm Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity and related metabolic diseases. Its commercial product is IMCIVREE (setmelanotide), and the company also develops additional product candidates for inherited and acquired obesity-related conditions.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSales of IMCIVREE to treat approved rare genetic obesity indications.
Named-patient and reimbursed access arrangements outside the United States.
License-related revenue or reductions tied to partnering arrangements.
Asiakkaat
Rhythm sells primarily to specialty pharmacies and distributors that dispense IMCIVREE to patients with rare genetic obesity disorders. Outside the United States, it also sells through specialty distributors, retail pharmacy chains, and hospitals, including government-owned or supported institutions. The end users are patients with conditions such as POMC, LEPR, and BBS-related obesity, while payers and reimbursement authorities strongly influence access and uptake.
Buys IMCIVREE for dispensing to U.S. patients; critical because it accounts for the largest share of revenue.
Buy and distribute product in markets where access is achieved through local distribution partners.
Dispense IMCIVREE in certain non-U.S. markets where pharmacy-based access is available.
Purchase for patients treated in institutional settings, especially outside the U.S.
The ultimate end users; demand depends on diagnosis, reimbursement, and physician adoption.
Strategia
Rhythm’s strategy centers on expanding global commercialization of IMCIVREE while broadening access into additional countries and indications. It also continues clinical development of follow-on programs such as RM-718 and bivamelagon, aiming to extend its rare-obesity franchise beyond the current commercial product.
Revenue growth depends on diagnosis, reimbursement, and physician adoption across more markets.
New approved uses can enlarge the treatable population and support longer-term growth.
Additional assets reduce dependence on a single product and extend the franchise.
The company relies on third-party CMOs for API and finished drug product.
Maantiede
Q3/2024The United States is the company’s largest market and the main source of product revenue, with the majority of sales generated there in recent periods. Internationally, Rhythm has achieved market access or named-patient sales in more than 20 countries and sells through local distributors, pharmacies, and hospitals. Geography matters because reimbursement, regulatory approval, and distribution structure differ materially by country and directly affect adoption and revenue mix.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Rhythm is exposed to commercialization risk because its business depends heavily on a single product, a limited number of distribution partners, and reimbursement decisions. It also faces typical biopharma risks around clinical development, regulatory approvals, manufacturing quality, and competition in the obesity market. Because production is outsourced, any CMO disruption or compliance issue could affect supply, approvals, and revenue.
- Dependence on a single commercial productVaikutus: KorkeaTodennäköisyys: Kohtalainen
A large share of revenue comes from IMCIVREE, so any demand, access, or safety issue would directly affect sales.
Kohdistuu: Commercial revenue concentration
- Specialty pharmacy and distributor concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on a small number of channel partners, especially in the U.S., which can disrupt revenue if changed.
Kohdistuu: Distribution channel
- Manufacturing dependence on CMOsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Rhythm does not manufacture its own drug product and depends on third parties for API and finished goods.
Kohdistuu: Supply chain and quality
- Regulatory and clinical development uncertaintyVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Pipeline programs and new indications require successful trials and approvals before they can contribute meaningfully.
Kohdistuu: Pipeline
- Competitive pressure in obesity therapeuticsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The obesity market is crowded and fast-moving, which can affect physician adoption, pricing, and market share.
Kohdistuu: Therapeutic competition
Kirjanpito
Harkinnanvaraiset erätIMCIVREE is sold net of discounts, rebates, and co-pay assistance, which requires judgment in estimating net sales.
Vaikutus: Affects reported product revenue and quarterly comparability
Specialty pharmacy and country-level access decisions can shift the timing of recognized revenue.
Vaikutus: Can create volatility in quarterly results
Termination or modification of licensing arrangements can lead to reductions of previously recognized revenue.
Vaikutus: Can cause one-time revenue reversals
A meaningful portion of operating expense includes equity-based pay for commercial, R&D, and administrative staff.
Vaikutus: Affects operating expense and comparability across periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
Fractyl Health, Inc
GUTS · Surgical & Medical Instruments & Apparatus
Fractyl Health is a U.S.-based metabolic therapeutics company developing device and gene-therapy approaches for obesity and type 2 diabetes.
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Palatin Technologies, Inc
PTN · Pharmaceutical Preparations
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
MetaVia Inc.
MTVA · Pharmaceutical Preparations
Päivitetty: 24.9.2026